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Abstract: The aim of this study was to
investigate the antibody response following
immunization with plasmid vector DNA
containing the hepatitis B virus core antigen
(HBcAg) gene of a hepatitis B virus (HBV)
isolated from a patient in Turkey. A HBcAg
gene fragment was cloned into a pcDNA 3
eukaryotic
expression
vector.
After
confirmation of the cloning of the HBcAg
gene, the expressing vector based HBcAg was
used in DNA immunization experiments. Fourto 6-week-old Balb/c mice were immunized
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Introduction
Recent studies have shown that the injection of
foreign DNA into muscle induces an immune response to
the DNA-encoded protein (1,2). DNA immunization has
the ability to induce both cell-mediated and humoral
immunity. In addition, DNA-based immunization also
lends itself to the design of multivalent immunogens
targeted at various pathogens. This may facilitate
economical immunization in developing countries. Thus,
DNA-based immunization is a newly developed method of
vaccination that has already been applied to prevent a
wide range of infectious diseases (1,2).
Chronic hepatitis B virus (HBV) infection may lead to
hepatocellular carcinoma (3,4). Individuals who are
chronic carriers of the hepatitis B virus (HBV) have a
greater than 100-fold increased relative risk of
developing this tumor. The incidence of this cancer is
rising globally and it is thus essential that means be found
to prevent this lethal disease by prophylactic and
therapeutic immunization (3-5). It has been reported by
several researchers that DNA vaccines specific for
hepatitis B virus (HBV) antigens induce a strong humoral
and cell-mediated immunity in mice and other
experimental animal models (6-8).

with HBcAg expressing plasmids and the antiHBcAg antibody responses of the mice were
evaluated by enzyme immunoassay (EIA). The
results of this study indicated that HBcAg
expressed from pcDNA 3 based eukaryotic
expression vector induced an anti-HBcAg
response when introduced intramuscularly
into Balb/c mice.
Key Words: Hepatitis B virus, core antigen,
DNA immunization.

The hepatitis B virus core antigen is one of the major
viral proteins present on the virion. It is about 183 aa
long and has a molecular weight of 21 kDA (9). There are
conflicting reports on the role of the immune responses
to this protein (10,11). While some argue that the
immune response to HBcAg facilitates viral clearance
from the host, others favor the idea that anti-HBcAg T
cell response is the major cause of immunopathology
observed in the liver during HBV infection (5,12).
In the present study, we sought to investigate the
antibody response following immunization with plasmid
vector DNA containing a HBcAg gene segment.
Materials and Methods
In the present study, the HBcAg gene segment
amplified by a polymerase chain reaction (PCR) from HBV
positive human serum was cloned into pUC19 plasmid, as
desribed earlier (13). Later, HBcAg was excised from
pUC-HBc with Eco RI and Hind III and inserted into a
pcDNA3 eukaryotic expression vector (13,14). The
recombinant plasmid (pcD-HBc) containing HBcAg gene
inserts was identified with Eco RI and Hind III restriction
endonucleases. Further conformation of the presence of
the HBcAg gene into pcD-HBc was carried out with PCR
(13,14).
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PCR of pcD-HBc, an amplification product 550 bp long
was visualized on a 1.5% agarose gel (Figure 1, Lane 4).
The results of anti-HBcAg antibody responses
following the first and second immunizations as
determined by sandwich EIA are shown in Figure 2. After
the first immunization, four out of the 10 animals had
antibody titers whereas all the animals had increased antiHBcAg antibodies after the second immunization.
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For confirmation of the cloned HBcAg gene in pcDNA3
restriction endonuclease analysis on the recombinant
plasmid pcD-HBc was carried out. The results of the
analysis showed that the fragment excised into pcD-HBc
with Hind III and Eco RI was about 550 base pairs (bp)
long (Figure 1, lane 6). In further confirmation with the
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A 100 µg sample of the recombinant plasmid DNA
(pcD-HBc) in 100 µl 0.01 M of phosphate buffered saline
(PBS) was injected into the right tibial muscle of each
mouse (1). The control animals received PBS only. After
2 weeks of immunizations, the animals were bled retroorbitally for serum extraction. The resulting sera were
tested for the presence of anti-HBcAg antibodies by a
commercially available enzyme immunoassay (EIA) kit
(Abbott Murex, Wiesbaden, Germany) (15). Booster
immunizations were carried out with pcD-HBc 1 month
after the first immunization; 2 weeks after the boost,
blood samples were obtained and the sera were tested as
mentioned earlier.

The results of anti-HBcAg antibody responses were determined by sandwich enzyme immunoassay.

Discussion
In the present study, we demonstrated that HBcAg
expressed from a plasmid vector induced a detectable
antibody response in Balb/C mice. Antibody response was
shown to be induced in four out of 10 immunized mice
following the first injection of plasmid DNA. However,
after the second immunization, an antibody response was
noted in all the animals. Similar findings have been
reported by other researchers (1,2).
HBcAg specific cytotoxic T and CD4+ T lymphocyte
responses are thought to play a role in the clearance of
acute and chronic HBV infections (12,16). In the present
study, only the antibody response was investigated. It
would be of interest to determine CTL and CD4+ helper T
cell activity in these mice.
Figure 1.
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Confirmation with restriction endonuclease analysis and
PCR of the cloning of the HBcAg gene into a eukaryotic
expression vector. Lane 1: Uncut pcD-HBc, Lane 2: 100 bp
DNA ladder; Lane 3: PCR products amplified from
pcDNA3; Lane 4: About 560 bp PCR products amplified
from pcD-HBc; Lane 5: Hind III cut Lambda DNA marker;
and Lane 6: Hind III and Eco RI cut pcD-HBc.

There are a number of reports in the literature
indicating that vectors carrying HBV core antigen
sequences are effective in inducing anti-HBcAg immune
reactions in chimpanzees and mice (6,17). In our model,
we aimed to test the immunogenicity of HBcAg. After the
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establishment of the model, other more effective vectors
or other forms of the antigen would be investigated. It
has been demonstrated with nucleic acid based vaccines
that the plasmid DNA introduced into the muscle tissue
would be taken up primarily by myocytes (2,18). It has
also been postulated that some DNA would also enter
dendritic cells and/or leak into the lymphatic drainage and
reach local lymph nodes (2). Antigen carried into the
tissues by the vector was shown to be processed and
presented by both major histocompatibility complex
molecules (1,2,18). In our study, we did not investigate
the fate of the injected DNA. However, from the presence
of antibody responses it would be inferred that at least

some HBcAg encoding plasmid DNA reached the
appropriate antigen presenting cells, and HBcAg was
processed and presented to the pathway leading to
recognition by CD4+ T lymphocytes. In future studies, the
level of expression of HBcAg and the other arms of
immunity stimulated by the expressed protein deserve to
be researched.
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